Histopathology and prognosis of de novo XXXX following solid organ transplantation.

@entity1 @entity5 @entity189 @entity150 @entity652
BACKGROUND: @entity1 following solid organ transplantation have an increased risk of developing de novo @entity150 , but their biology is poorly characterized. METHODS: We studied 1743 @entity1 who underwent a transurethral resection of a newly diagnosed @entity150 at a single institution. The histopathology, treatment, recurrence-free survival and overall survival were evaluated and compared between transplant and non-transplant @entity1 . RESULTS: We identified 74 transplant @entity1 who developed a de novo @entity150 after a median post-transplantation interval of 62  months. The @entity5 was malignant in 29 @entity1 (39  %). The most common benign lesion was @entity652 (84  %), which neither coexisted with nor developed into @entity5 during follow-up. Compared with non-transplant @entity1 (n  =  1669), transplant @entity1 were significantly younger (median 55 vs 69  years, P  <  0.001) and had a 9.0-fold higher odds of @entity5 (P  <  0.001), while there were no differences in pathology among @entity1 with @entity189 of the bladder (UCB). In a multivariable analysis for non-muscle-invasive UCB that was adjusted for the risk group, @entity1 with a transplant had a 1.8-fold increased risk of recurrence (P  =  0.048). Four of five transplant @entity1 did not respond to Bacillus Calmette-Gu  rin instillations. There were no differences in overall survival after radical cystectomy (P  =  0.87). CONCLUSIONS: The majority of @entity150 in transplant @entity1 are benign, and they neither coexist with nor develop into @entity5 . Transplant @entity1 with non-muscle-invasive UCB show an increased risk of disease recurrence, while those treated with radical cystectomy have similar outcomes to @entity1 without a transplant.
